{"disease":{"id":"glomerulopathy","name":"glomerulopathy"},"drugs":{"marketed":[{"drug_id":"iptacopan","indication_name":"Complement 3 Glomerulopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fabhalta","generic_name":"IPTACOPAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Factor B","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Iptacopan binds to Factor B, regulating C3 cleavage and downstream effects in the alternative complement pathway, controlling IVH and EVH in PNH and inhibiting local activation in IgAN and C3G."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT00524992","title":"Evaluation of Albuminuria HIV-Infected Patients","phase":"","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT03955445","title":"Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06858319","title":"Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07010250","title":"Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":146,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05067127","title":"Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07029542","title":"Home Reported Outcomes in C3G Study","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07331259","title":"CHART-C3G/CLNP023B12011","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":83,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05083364","title":"Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Arrowhead Pharmaceuticals","has_results":false},{"nct_id":"NCT05294770","title":"Dietary Intervention in Obesity-related Glomerulopathy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","has_results":false},{"nct_id":"NCT03301467","title":"Controlled Trial Evaluating Avacopan in C3 Glomerulopathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07156149","title":"Fabhalta Capsules Specified Drug-use Survey","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06786338","title":"A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":38,"lead_sponsor_name":"Suzhou Sanegene Bio Inc.","has_results":false},{"nct_id":"NCT07522099","title":"Chinese Adults With Kidney Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"ADARx Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT00255398","title":"Kidney Disease Biomarkers","phase":"","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT03459443","title":"A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07416162","title":"A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":21,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03380962","title":"Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Stanley Jordan, MD","has_results":false},{"nct_id":"NCT05428605","title":"In Vitro Immunomodulation in Membranous Nephropathy Relapses","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT03369236","title":"A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT00098020","title":"Podocyte Retinoids","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":true},{"nct_id":"NCT03380377","title":"Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Stanley Jordan, MD","has_results":true},{"nct_id":"NCT03723512","title":"Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Mario Negri Institute for Pharmacological Research","has_results":false},{"nct_id":"NCT03124368","title":"A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05162066","title":"Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"BioCryst Pharmaceuticals","has_results":true},{"nct_id":"NCT04729062","title":"C3G/Primary IC-MPGN EAP","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05222412","title":"Managed Access Programs for LNP023, Iptacopan","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":27},"guidelines":[],"source":"Drug Landscape verified database"}